New scan method could Fine-Tune prostate cancer therapy
NCT ID NCT06479187
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study explores whether special PET scans (PSMA-PET) can better track how well treatment is working in men with metastatic hormone-sensitive prostate cancer. Twenty participants will receive standard care and undergo scans before and after 6 months of treatment. The goal is to see if scan results match other disease markers like PSA levels, potentially guiding future treatment decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HORMONE SENSITIVE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Chemo combo vs. radioactive drug: which tames aggressive prostate cancer?
- Can a blood filtering technique reveal more about prostate cancer spread?
- Can a vaccine plus immune booster tackle resistant prostate cancer?
- Can a smart drug deliver a toxic payload to prostate cancer cells?
- Can a new chemo schedule tame side effects in prostate cancer?
- Can a blast of testosterone shrink hard-to-treat prostate cancer?